NeoGenomics, Inc. announced that Alicia Olivo, Executive Vice President, General Counsel and Business Development, will transition from her role and cease serving as General Counsel effective September 21, 2026. Ms. Olivo will remain an employee until October 2, 2026 for transitional purposes and is eligible for separation payments consistent with her employment agreement. This executive departure represents a material change in key leadership. NeoGenomics operates in the healthcare industry, providing molecular diagnostic testing services.
